Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corporation (Nasdaq: SWKH) is a life science focused specialty finance company that regularly reports on its financial performance, portfolio activity, and strategic transactions. As a provider of non-dilutive financing to small- and mid-sized commercial-stage healthcare companies, SWK’s news flow centers on its finance receivables portfolio, royalty monetization activity, and developments within its pharmaceutical development services operations.
Readers of this SWKH news page can expect updates on quarterly and annual financial results, including GAAP net income, segment-level non-GAAP metrics, effective yields on finance receivables, and changes in book value and tangible finance book value per share. The company frequently issues press releases in connection with its earnings reports and hosts conference calls to discuss its corporate and financial results.
SWK’s news also highlights portfolio transactions such as new term loans, expansions of existing credit facilities, sales and monetizations of royalty portfolios, and resolutions of nonaccrual positions or workout situations. Announcements have included the monetization of royalty assets, special dividends funded by those monetizations, and updates on loan payoffs and recoveries.
In addition, the company discloses strategic and corporate events, including its Agreement and Plan of Merger with Runway Growth Finance Corp., as well as updates on its pharmaceutical development subsidiaries. Investors following SWKH news gain insight into how SWK manages its life science finance portfolio, how non-GAAP measures relate to reported results, and how strategic transactions may affect stockholders. For those tracking the specialty finance and healthcare capital markets, this page offers a focused stream of company-issued information and regulatory news related to SWK Holdings Corporation.
Enteris BioPharma, a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), will host a webinar on September 29, 2020, at 1 p.m. ET, featuring Dr. John Vrettos. The webinar will focus on innovative approaches to oral peptide delivery, addressing challenges in drug formulation and delivery. Enteris' proprietary technology, Peptelligence, enables effective oral delivery of peptides and peptidomimetics, enhancing drug compliance and market opportunities. Dr. Rajiv Khosla emphasized the potential of oral peptide therapeutics to transform treatment strategies.
Summary not available.
SWK Holdings Corporation (Nasdaq: SWKH) announced participation in the virtual 2020 Colliers Institutional Investor Conference on September 10, 2020. Chairman and CEO Winston Black will host one-on-one meetings with institutional investors to discuss the company's business strategies, recent achievements, and future milestones. SWK focuses on specialty finance solutions in the healthcare sector, partnering with product marketers to create long-term value while minimizing equity dilution. Additional information is available on their website.
SWK Holdings Corporation reported strong second quarter 2020 results, with total revenue of $7.9 million, up 40% from $5.7 million in 2019. The specialty finance segment achieved a 12.2% adjusted ROIC, with assets reaching $178.7 million, a 5.3% year-over-year increase. GAAP net income was $0.9 million or $0.07 per diluted share. The company acquired Enteris BioPharma, enhancing its portfolio. SWK was added to the Russell 3000™, 2000™, and Microcap™ Indexes, improving visibility and liquidity.
SWK Holdings Corporation (Nasdaq: SWKH) will host a conference call on August 17, 2020, at 10:00 a.m. ET, to discuss its second quarter 2020 financial results. Interested parties can join the call by dialing (844) 378-6488 (U.S.) or (412) 317-1079 (international). An audio webcast will be available on their website, with an archive accessible for 90 days following the event. SWK specializes in providing flexible financing solutions in the healthcare sector, enhancing partnership opportunities for product marketers and royalty holders.
SWK Holdings Corporation (Nasdaq: SWKH) announced that Chairman and CEO Winston Black will present at the Life Sciences Investor Forum on June 25, 2020, at 11:30 a.m. ET. The event allows for real-time investor interaction, with an archived webcast available later. Black will outline SWK's strategy of providing capital to small and mid-sized life sciences companies, facilitating deals from $5 million to $20 million. To date, SWK has executed transactions totaling $540.1 million across 36 parties, focusing on flexible financing solutions in the healthcare sector.